Provectus Biopharmaceuticals, Inc. announced a $3 million seed financing round for VisiRose, Inc., its newly launched ophthalmology-focused subsidiary. This funding is designated to support the advancement of VisiRose's ocular therapeutics pipeline.
The seed financing specifically enables VisiRose to progress its lead drug candidate, PV-305, through critical initial regulatory steps. This capital is crucial for VisiRose's development efforts in corneal diseases and other serious ocular conditions.
Dominic Rodrigues, Acting Chief Executive Officer of VisiRose, stated that the funding moves VisiRose and Provectus closer to providing innovative therapies to patients. This financing strategy aims to attract investment specifically for the ophthalmology program without solely relying on the parent company's capital.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.